NAMMI THERAPEUTICS
Live / Registered — Registered — Sections 8 & 15 accepted and acknowledged (as of 05 Apr 2025)
What this means for you
Registered since 19 Nov 2019. The owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 88317134
- Registration number
- 5916753
- Mark type
- Stylized text
- Filed
- 26 Feb 2019
- Published for opposition
- 25 Jun 2019
- Registered
- 19 Nov 2019
- Attorney of record
- Britt L. Anderson
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations for use in immunotherapy; tumor suppressing agents; pharmaceutical products for the treatment of cancer and tumors; pharmaceuticals, namely, immunogenic cell death inducers; therapeutic agents for promotion of cancer immunity
Owner
- NAMMI THERAPEUTICS, INC.,, LOS ANGELES, CA, US
- NAMMI OPS, INC., LOS ANGELES, CA, US
- Nammi Therapeutics, Inc., Los Angeles, CA, US
- Nammi Therapeutics, Inc., Los Angeles, CA, US
- Nammi Therapeutics, Inc., Los Angeles, CA, US
Prosecution history
- 05 Apr 2025 — NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED
- 05 Apr 2025 — REGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.
- 05 Apr 2025 — CASE ASSIGNED TO POST REGISTRATION PARALEGAL
- 20 Dec 2024 — TEAS SECTION 8 & 15 RECEIVED
- 19 Nov 2024 — COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
- 31 Mar 2021 — AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
- 03 Mar 2021 — AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
- 19 Nov 2019 — REGISTERED-PRINCIPAL REGISTER
- 12 Oct 2019 — NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
- 11 Oct 2019 — ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
- 07 Oct 2019 — STATEMENT OF USE PROCESSING COMPLETE
- 17 Sept 2019 — USE AMENDMENT FILED
- 07 Oct 2019 — CASE ASSIGNED TO INTENT TO USE PARALEGAL
- 17 Sept 2019 — TEAS STATEMENT OF USE RECEIVED
- 20 Aug 2019 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT